Sign Up to like & get
recommendations!
0
Published in 2022 at "Journal of Biopharmaceutical Statistics"
DOI: 10.1080/10543406.2022.2065876
Abstract: Dear Editor, In my original paper of the bridging study, the estimates of mean and variance for the treatment efficacy for CDx+ patient population are assumed to be independent, a typical assumption for an independent…
read more here.
Keywords:
mean variance;
bridging study;
variance;
medicine ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15035
Abstract: INTRODUCTION Fuzuloparib, also known as fluzoparib or SHR3162, is a poly ADP-ribose polymerase (PARP) inhibitor developed for the treatment of malignant tumor. Three specifications of fuzuloparib capsules (10mg, 40mg and 100mg) were originally developed for…
read more here.
Keywords:
randomized open;
fuzuloparib capsules;
period;
study ... See more keywords